• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受肾输尿管切除术的上尿路尿路上皮癌患者局部区域复发的预测因素和辅助放疗靶区的划定。

Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy.

机构信息

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.

Department of Urology, Mayo Clinic, Rochester, Minnesota.

出版信息

Pract Radiat Oncol. 2021 Sep-Oct;11(5):e468-e476. doi: 10.1016/j.prro.2021.02.005. Epub 2021 Feb 23.

DOI:10.1016/j.prro.2021.02.005
PMID:33636378
Abstract

PURPOSE

To identify factors predictive of locoregional recurrence (LRR) in upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy and to propose adjuvant radiation therapy (ART) fields.

METHODS AND MATERIALS

Clinical and pathologic variables for patients receiving nephroureterectomy for UTUC between 1995 and 2009 were analyzed for associations with outcomes. Sites of LRR from all patients with available imaging (39) were contoured on computed tomography image sets of patients with representative anatomy, and ART fields were proposed based on these distributions.

RESULTS

A total of 279 patients with a median follow-up of 13.0 years were analyzed. The 5-year cumulative incidence of LRR was 16.7% (95% CI, 12.2-21). Pathologic risk factors (PRFs) associated with increased risk of LRR included tumor in both the renal pelvis and ureter, T stage ≥2, lymph node involvement, grade 3 histology, and positive surgical margins (P < .05). Patients with an increased number of PRFs had a significantly greater risk of LRR. The 5-year cumulative incidence estimates of LRR were 5.3% (95% CI, 1.8%-16.0%), 15.6% (95% CI, 9.5%-25.7%), and 43.9% (95% CI, 31.1%-62.1%) for those with 1, 2, and ≥3 PRFs, respectively. ART fields covering the renal fossa and retroperitoneal lymph nodes from the superior border of L1 through the aortic bifurcation would encompass all sites of LRR for 33 of 46 patients (72%). Non-LRR bladder and distant failure occurred in 101 (36.2%) and 73 (26.2%) of the patients, respectively. The 5-year cumulative incidence estimate of distant failure was 22.5% (95% CI, 17.4%-27.3%).

CONCLUSIONS

In patients receiving nephroureterectomy for UTUC, LRR is significantly increased in patients with 2 or more PRFs. These data provide clinically valuable insight into the selection of candidates for ART and the design of ART fields.

摘要

目的

确定接受肾输尿管切除术治疗的上尿路上皮癌(UTUC)患者局部区域复发(LRR)的预测因素,并提出辅助放疗(ART)的靶区。

方法和材料

分析了 1995 年至 2009 年间接受肾输尿管切除术治疗 UTUC 的患者的临床和病理变量,以评估其与结局的关系。对所有有影像学检查(39 例)的患者的 LRR 部位进行了勾画,并根据这些分布情况提出了 ART 靶区。

结果

共分析了 279 例中位随访时间为 13.0 年的患者。5 年 LRR 的累积发生率为 16.7%(95%CI,12.2%-21)。与 LRR 风险增加相关的病理危险因素(PRFs)包括肾盂和输尿管均有肿瘤、T 分期≥2、淋巴结受累、G3 组织学和切缘阳性(P<.05)。具有较多 PRFs 的患者 LRR 风险显著增加。5 年 LRR 的累积发生率估计值分别为 5.3%(95%CI,1.8%-16.0%)、15.6%(95%CI,9.5%-25.7%)和 43.9%(95%CI,31.1%-62.1%),分别为有 1、2 和≥3 个 PRFs 的患者。覆盖 L1 上缘至主动脉分叉的肾窝和腹膜后淋巴结的 ART 靶区将包括 46 例患者中的 33 例(72%)的所有 LRR 部位。非 LRR 膀胱和远处失败分别发生在 101 例(36.2%)和 73 例(26.2%)的患者中。5 年远处失败的累积发生率估计值为 22.5%(95%CI,17.4%-27.3%)。

结论

在接受肾输尿管切除术治疗 UTUC 的患者中,2 个或更多 PRFs 的患者 LRR 显著增加。这些数据为选择接受 ART 的患者和设计 ART 靶区提供了有价值的临床见解。

相似文献

1
Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy.接受肾输尿管切除术的上尿路尿路上皮癌患者局部区域复发的预测因素和辅助放疗靶区的划定。
Pract Radiat Oncol. 2021 Sep-Oct;11(5):e468-e476. doi: 10.1016/j.prro.2021.02.005. Epub 2021 Feb 23.
2
Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma.肾输尿管切除术治疗上尿路上皮癌后局部复发的模式和危险因素。
World J Surg Oncol. 2020 May 30;18(1):114. doi: 10.1186/s12957-020-01877-w.
3
Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis.辅助放疗在上尿路尿路上皮癌中的应用:系统评价和荟萃分析。
Curr Oncol. 2022 Dec 20;30(1):19-36. doi: 10.3390/curroncol30010002.
4
Nephroureterectomy vs. segmental ureterectomy of clinically localized, high-grade, urothelial carcinoma of the ureter: Practice patterns and outcomes.肾输尿管切除术与节段性输尿管切除术治疗临床局限性、高级别、输尿管尿路上皮癌:实践模式和结果。
Urol Oncol. 2020 Nov;38(11):851.e1-851.e10. doi: 10.1016/j.urolonc.2020.08.004. Epub 2020 Aug 26.
5
Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy.根治性肾输尿管切除术后上尿路尿路上皮癌膀胱复发的风险分层
BJU Int. 2015 May;115(5):705-12. doi: 10.1111/bju.12707. Epub 2015 Jan 21.
6
Clinical implications of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma.根治性肾输尿管切除术治疗上尿路尿路上皮癌后膀胱内复发的临床意义。
Int J Urol. 2016 May;23(5):378-84. doi: 10.1111/iju.13054. Epub 2016 Jan 18.
7
Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.非肌层浸润性膀胱肿瘤史对上尿路尿路上皮癌患者的预后意义。
Urol Oncol. 2013 Nov;31(8):1615-20. doi: 10.1016/j.urolonc.2012.03.004. Epub 2012 Apr 21.
8
Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma.浸润性上尿路上皮癌的预后因素和风险分层。
Clin Genitourin Cancer. 2018 Aug;16(4):e751-e760. doi: 10.1016/j.clgc.2018.01.014. Epub 2018 Feb 6.
9
Upper urinary tract recurrence following bladder cancer therapy: a review of surveillance and management.膀胱癌治疗后上尿路复发:监测与管理的综述。
Curr Opin Urol. 2019 May;29(3):189-197. doi: 10.1097/MOU.0000000000000598.
10
The characteristics of recurrent upper tract urothelial carcinoma after radical nephroureterectomy without bladder cuff excision.根治性肾输尿管切除术未切除膀胱袖口状组织后复发性上尿路尿路上皮癌的特征
Yonsei Med J. 2015 Mar;56(2):375-81. doi: 10.3349/ymj.2015.56.2.375.

引用本文的文献

1
A rare case of retroperitoneal recurrence as squamous cell carcinoma 10 years after nephroureterectomy.1例肾输尿管切除术后10年出现腹膜后复发鳞状细胞癌的罕见病例。
IJU Case Rep. 2024 Nov 4;8(1):56-59. doi: 10.1002/iju5.12809. eCollection 2025 Jan.